Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLTE
HOLDBelite Bio, Inc · Healthcare · United States · $6.1B · Avg Vol: $31M/d
COMPANY DESCRIPTION
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases. The company targets serious eye diseases with high unmet medical needs, such as Stargardt disease and dry Age-related Macular Degeneration (AMD), leveraging its proprietary drug candidates. Belite Bio is a specialized ophthalmology biotech firm, dedicated to advancing treatments for degenerative eye conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 242.8M | — |
| EPS | — | -0.63 | -1.19 | -1.18 | -2.31 | — | -2.59 | -3.30 | 0.95 | — |
| Shares | — | 24.9M | 29.1M | 31.8M | 39.3M | +58.0% | 40.1M | — | — | — |
| Debt | — | 0.9M | 0.9M | 0.5M | 0.4M | -20.9% | — | — | — | — |
| Equity | — | 41.5M | 90.4M | 145.8M | 770.5M | 164.8% | — | — | — | — |
| Op CF | — | -11.5M | -29.8M | -29.2M | -37.0M | — | -37.0M | — | — | — |
| Inv CF | — | -0.4M | -63.0K | -110.6M | -305.1M | — | — | — | — | — |
| Fin CF | — | 37.0M | 76.0M | 83.6M | 663.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLTE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLTE | Belite Bio, Inc(you) | $6.1B | 36 | HOLD |
| DNTH | Dianthus Therapeutics, Inc. | $5.7B | 35 | SELL |
| ORKA | Oruka Therapeutics, Inc. | $5.6B | 35 | SELL |
| DFTX | Definium Therapeutics, Inc. | $5.7B | 39 | HOLD |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| IMVT | Immunovant, Inc. | $8.1B | 39 | HOLD |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 30 | SELL |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | SELL |
| PTCT | PTC Therapeutics, Inc. | $6.4B | 46 | HOLD |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.6%